Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

NOVARTIS FARMA - PRODUTOS FARMACÊUTICOS S.A.

NIF 500063524
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €27,739,283 114 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €27,739,283 114 contracts
A2 · Late Publication €34,704,041,648 6,362 contracts
Contract published to BASE more than 10 days after the signing date
LOW €34,704,041,648 6,362 contracts
A5 · Threshold Splitting €18,910,293 246 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €18,910,293 246 contracts
A6 · Low Competition €1,942,934,630 157 contracts
Only one bidder participated in a competitive procedure
MEDIUM €1,942,934,630 157 contracts
A9 · Price Overrun €27,611 6 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €5,886 4 contracts
MEDIUM €21,725 2 contracts
A9 · Abnormal Price Reduction €44,020,437,901 2,347 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €44,020,437,901 2,347 contracts
B5 · Benford's Law Deviation €945,690,369 3 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €945,690,369 3 contracts
C3 · Missing Mandatory Fields €20,114,261 140 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €20,114,261 140 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

721
€6,560,012,322
21
€1,706,982,625
83
€1,427,879,106
213
€1,411,631,183
643
€1,398,117,630
112
€1,349,883,692
390
€1,320,940,652
969
€1,301,392,469
68
€1,281,738,297
529
€1,276,921,062
244
€1,230,279,090
60
€1,211,033,625
77
€1,200,736,458
127
€1,177,521,481
533
€1,153,046,826
165
€1,152,381,205
49
€1,101,696,609
31
€1,070,003,402
55
€1,035,456,897
223
€1,028,272,147
Page 1 of 4 · 72 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 4 · 157 contracts

AL B) EXCL SPMS (2024_0780) VARIOS
PT · 12397767 · Ao abrigo de acordo-qu...
A6 · Low Competition
€121,240 2026-01-02
BEAD20250272 - AQUISIÇÃO DE OUTROS PRODUTOS EM OFTALMOLOGIA-RANIBIZUMAB
PT · 11312708 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A6 · Low Competition
€19,218 2025-03-27
INIBIDORES DE TIROSINACINASES - EVEROLÍMUS
PT · 11307010 · Ao abrigo de acordo-qu...
A6 · Low Competition
€69,841 2025-03-26
INIBIDORES DE TIROSINACINASES - TRAMETINIB
PT · 11306956 · Ao abrigo de acordo-qu...
A6 · Low Competition
€229,476 2025-03-26
INIBIDORES DE TIROSINACINASES - PAZOPANIB
PT · 11305950 · Ao abrigo de acordo-qu...
A6 · Low Competition
€89,324 2025-03-25
ANTI-HIPERTENSORES - SACUBITRIL + VALSARTAN
PT · 11305789 · Ao abrigo de acordo-qu...
A6 · Low Competition
€14,875 2025-03-25
BEAD20250156 - AQUISIÇÃO DE IMUNOMODULADORES - RIBOCICLIB - 1º SEMESTRE
PT · 11299648 · Ao abrigo de acordo-qu...
A6 · Low Competition
€340,489 2025-03-20
BEAD20250126 - AQUISIÇÃO DE IMUNOMODULADORES - SECUCINUMAB
PT · 11295635 · Ao abrigo de acordo-qu...
A6 · Low Competition
€218,091 2025-03-20
IMUNOMODULADORES - CICLOSPORINA, OFATUMUMAB E SIPONIMO
PT · 11277220 · Ao abrigo de acordo-qu...
A6 · Low Competition
€169,112 2025-03-12
2025002002 – Aquisição de medicamentos
PT · 11275604 · Ajuste Direto Regime G...
A6 · Low Competition
€110,510 2025-03-11
INIBIDORES DE TIROSINACINASES - RUXOLITINIB
PT · 11299364 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€248,329 2025-02-27
ANTIASMÁTICOS - OMALIZUMAB
PT · 11253619 · Ao abrigo de acordo-qu...
A6 · Low Competition
€15,909 2025-02-27
2025001727 – Aquisição de medicamentos
PT · 11251093 · Ajuste Direto Regime G...
A6 · Low Competition
€10,263 2025-02-26
Fornecimento de Omalizumab, Ribociclib, Nilotinib, Secucinumab, Erenumab, Ruxolitinib e OFATUmumab ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 11245324 · Ajuste Direto Regime G...
A6 · Low Competition
€525,168 2025-02-24
Fornecimento de Everolímus ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 11238696 · Ajuste Direto Regime G...
A6 · Low Competition
€34,649 2025-02-20
2025000708 – Aquisição de medicamentos
PT · 11211131 · Ajuste Direto Regime G...
A6 · Low Competition
€20,526 2025-02-05
Aquisição Medicamentos Exclusivos Novartis Farma – Ano 2025
PT · 11264122 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€95,144 2025-01-27
C/ BASE NO CPA 2023_671
PT · 11229455 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€3,710,282 2025-01-23
C/ BASE NO CPA 2024_781
PT · 11197121 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€1,868,664 2025-01-16
MEDICAMENTOS EXCLUSIVOS _ NOVARTIS
PT · 11223347 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€40,000 2025-01-15
AE/3476/2024 - ALPELISIB 50MG+200MG CP
PT · 11287311 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€16,000 2024-12-26
INIBIDORES DE TIROSINACINASES - TRAMETINIB
PT · 11088559 · Ao abrigo de acordo-qu...
A6 · Low Competition
€12,356 2024-12-16
BEAD20240433 - AQUISIÇÃO DE INIBIDORES DE TIROSINACINASES - RUXOLITINIB
PT · 11088413 · Ao abrigo de acordo-qu...
A6 · Low Competition
€26,449 2024-12-16
INIBIDORES DE TIROSINACINASES - NILOTINIB
PT · 11088234 · Ao abrigo de acordo-qu...
A6 · Low Competition
€10,678 2024-12-16
INIBIDORES DE TIROSINACINASES - DABRAFENIB
PT · 11087655 · Ao abrigo de acordo-qu...
A6 · Low Competition
€9,459 2024-12-16
Aquisição de Imatinib 100 mg comp
PT · 11282617 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€5,885 2024-12-16
Aquisição do Medicamento Brolucizumab [120 MG/ML; SOL INJ; SERINGA] Para a ULSCB
PT · 11096140 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€15,971 2024-12-06
Q1/25/2025 AGREGAÇÃO URGENTE - ELTROMBOPAG 50 MG COMP
PT · 11313258 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€56,938 2024-12-03
Aquisição do medicamento - alpelisib
PT · 11167359 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€6,400 2024-11-26
2024008291 – Aquisição de medicamentos
PT · 11054458 · Ajuste Direto Regime G...
A6 · Low Competition
€17,093 2024-11-25
IMUNOMODULADORES - FINGOLIMOD
PT · 11053052 · Ajuste Direto Regime G...
A6 · Low Competition
€136,237 2024-11-25
Aquisição de OFATUmumab 20 mg/0.4 ml Sol inj Caneta 0.4 ml SC ao Abrigo do AQ 2023/491
PT · 11044179 · Ao abrigo de acordo-qu...
A6 · Low Competition
€38,400 2024-11-19
INIBIDORES DE TIROSINACINASES - RUXOLITINIB
PT · 11014021 · Ao abrigo de acordo-qu...
A6 · Low Competition
€26,449 2024-11-08
BEAD20240451 - AQUSISIÇÃO DE IMUNOMODULADORES - RIBOCICLIB
PT · 11002602 · Ao abrigo de acordo-qu...
A6 · Low Competition
€157,148 2024-10-31
AQUISIÇÃO DE IMATINIB - 2024 - UNIDADE LOCAL DE SAÚDE LISBOA OCIDENTAL, EPE.
PT · 11005576 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€40,383 2024-10-24
2024005971 – Aquisição de medicamentos
PT · 11006730 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€23,957 2024-10-23
OUTROS PRODUTOS EM OFTALMOLOGIA -BROLUCIZUMAB
PT · 10976321 · Ao abrigo de acordo-qu...
A6 · Low Competition
€15,971 2024-10-17
ANTIASMÁTICOS - OMALIZUMAB
PT · 10970258 · Ao abrigo de acordo-qu...
A6 · Low Competition
€41,865 2024-10-15
BEAD20240379 - AQUISIÇÃO DE INIBIDORES DE TIROSINACINASES - PAZOPANIB
PT · 10968914 · Ao abrigo de acordo-qu...
A6 · Low Competition
€26,674 2024-10-14
Ajuste direto para aquisição de R1090 - Ranibizumab [10 mg/ml; 0,23; intravitreo; f/amp] doentes em tratamento, E574 - Everolímus [2.5 mg; cáp/comp], I202 - Imatinib [100mg; cáp/comp] e I258 - Imatinib [400 mg; cáp/comp].
PT · 10965731 · Ajuste Direto Regime G...
A6 · Low Competition
€12,857 2024-10-11
BEAD20240391 - AQUISIÇÃO DE INIBIDORES DE TIROSINACINASES - EVEROLÍMUS - 3MESES
PT · 10944578 · Ao abrigo de acordo-qu...
A6 · Low Competition
€16,274 2024-09-30
Q1/2927/2024 - ELTROMBOPAG 50 MG COMP
PT · 11677693 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€79,081 2024-09-23
LUTÉCIO (177LU) VIPIVOTIDO TETRAXETANO 1000 MBQ/ML SOL INJ FR 7.5 - 12.5 ML IV
PT · 11175743 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€600,000 2024-09-18
Aquisição de ALPELISIB 150 MG COMP
PT · 10917372 · Ajuste Direto Regime G...
A5 · Threshold Splitting A6 · Low Competition
€19,200 2024-09-05
BEAD20240457 - AQUISIÇÃO DE RANIBIZUMAB - 3 MESES
PT · 10898255 · Ao abrigo de acordo-qu...
A6 · Low Competition
€30,345 2024-09-02
INIBIDORES DE TIROSINACINASES - RUXOLITINIB (3MESES) EXCL NOVARTIS
PT · 10896933 · Ao abrigo de acordo-qu...
A6 · Low Competition
€26,449 2024-09-02
INIBIDORES DE TIROSINACINASES - MIDOSTAURINA - 3 MESES
PT · 10896946 · Ao abrigo de acordo-qu...
A6 · Low Competition
€46,184 2024-09-02
BEAD20240425 - AQUISIÇÃO DE INIBIDORES DE TIROSINACINASES - DABRAFENIB - 3 MESES
PT · 10894921 · Ao abrigo de acordo-qu...
A6 · Low Competition
€12,613 2024-08-30
J1/2643/2024 SECUCINUMAB 75 MG/0,5 ML SOL INJ SC
PT · 10889309 · Ajuste Direto Regime G...
A6 · Low Competition
€2,759 2024-08-23
Q1/2571/2024 - DABRAFENIB AUE n.º 202402549 e TRAMETINIB AUE n.º 202402550
PT · 10889288 · Ao abrigo de acordo-qu...
A6 · Low Competition
€192,571 2024-08-23
Next →
Overview
Total Value Won
€44,569,812,896
Contracts Won
8,946
Score 298645 · CRITICAL RISK
NIF
500063524
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.S. [P-c29c]
    vogal
    since 2025-04-02
  • A.C. [P-8633]
    Presidente
    since 2012-12-14
  • A.C. [P-8633]
    Presidente
    since 2014-08-04
  • A.C. [P-916a]
    Presidente
    since 2021-01-22
  • A.C. [P-916a]
    Presidente
    since 2022-12-20
  • A.C. [P-916a]
    Presidente
    since 2025-04-02
  • A.L. [P-d52d]
    Vogal
    since 2013-10-23
  • A.L. [P-d52d]
    Vogal
    since 2014-08-04
  • E.H. [P-cc53]
    Vogal
    since 2008-06-09
  • F.M. [P-2504]
    Vogal
    since 2008-06-09
  • I.T. [P-d95a]
    vogal
    since 2021-01-22
  • I.T. [P-d95a]
    Vogal
    since 2022-12-20
  • I.T. [P-d95a]
    vogal
    since 2025-04-02
  • J.M. [P-be67]
    Vogal
    since 2008-06-09
  • J.E. [P-8c90]
    Presidente
    since 2010-08-31
  • J.A. [P-c089]
    Vogal
    since 2011-04-13
  • J.J. [P-67b2]
    Vogal
    since 2016-03-02
  • J.C. [P-3763]
    Vogal
    since 2008-06-09
  • L.P. [P-79eb]
    Vogal
    since 2020-02-05
  • L.T. [P-36d3]
    Vogal
    since 2017-01-17
  • L.T. [P-36d3]
    Vogal
    since 2019-04-26
  • L.T. [P-36d3]
    Vogal
    since 2021-01-22
  • M.A. [P-0d16]
    Presidente
    since 2025-04-02
  • P.D. [P-fe5d]
    Vogal
    since 2022-12-20
  • P.L. [P-dfd3]
    vogal
    since 2021-01-22
  • P.L. [P-dfd3]
    Vogal
    since 2022-12-20
  • P.L. [P-dfd3]
    vogal
    since 2025-04-02
  • S.R. [P-807d]
    Presidente
    since 2021-04-13
  • S.R. [P-807d]
    Presidente
    since 2022-12-20
  • S.C. [P-44d9]
    Vogal
    since 2024-04-12
  • S.C. [P-44d9]
    vogal
    since 2025-04-02
  • S.A. [P-85b6]
    administradora
    since 2012-12-14
  • W.A. [P-9570]
    Vogal
    since 2013-10-23
  • W.A. [P-9570]
    Vogal
    since 2014-08-04
  • J.M. [P-74b5]
    Fiscal Único
    since 2008-06-09
  • J.M. [P-74b5]
    Fiscal Único
    since 2011-04-13
  • J.M. [P-74b5]
    Fiscal Único
    since 2014-08-04
  • J.M. [P-74b5]
    Fiscal Único
    since 2019-04-26
  • P.A. [P-4562]
    Fiscal Único
    since 2008-06-09
  • P.A. [P-4562]
    Fiscal Único
    since 2011-04-13
  • P.A. [P-4562]
    Fiscal Único
    since 2014-08-04
  • P.A. [P-4562]
    Fiscal Único
    since 2019-04-26
  • A.C. [P-8633]
    Presidente
    2019-04-26 → 2021-04-13
  • A.L. [P-d52d]
    Vogal
    2019-04-26 → 2019-05-23
  • C.S. [P-00f7]
    Vogal
    2014-08-04 → 2017-01-17
  • C.M. [P-004b]
    Vogal
    2019-05-23 → 2020-01-06
  • F.M. [P-2504]
    Vogal
    2011-04-13 → 2012-01-25
  • J.M. [P-be67]
    Vogal
    2011-04-13 → 2013-05-24
  • J.E. [P-8c90]
    Presidente
    2011-04-13 → 2012-09-19
  • J.J. [P-67b2]
    Vogal
    2019-04-26 → 2019-05-23
  • J.C. [P-3763]
    Vogal
    2011-04-13 → 2012-07-17
  • K.N. [P-34e6]
    Presidente
    2008-06-09 → 2010-08-31
  • L.P. [P-79eb]
    Vogal
    2022-12-20 → 2024-04-12
  • M.J. [P-dbeb]
    Administradora
    2012-04-27 → 2013-05-24
  • M.A. [P-8eb9]
    Vogal
    2008-10-28 → 2011-04-13
  • S.A. [P-85b6]
    Vogal
    2014-08-04 → 2016-03-02
  • W.A. [P-9570]
    Vogal
    2019-04-26 → 2019-05-23
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned